Table 1.

Key literature search findings, grouped by theme

Theme	Key findings
Adherence	Different biologics have different levels of adherence9
	Better adherence is observed when the dermatologist clarifies the treatment schedule10
	Better adherence is observed when the dermatologist keeps the patient informed and meets the patient's requests10
Decision making	No biological can be considered best for all patients11
	Patient preference should be a major deciding factor in biological choice11
	The dermatologist is the most important source for patient understanding of biologics, followed by research on the internet12
	The life course of patients has an impact on treatment strategies13, 14
	Fear of adverse effects is an important factor in patient preference11, 15
Quality of life	Treatment strategy has an impact on DLQI16
	Patients on topical and traditional systemic therapies have higher DLQI scores16, 17
	Patients with high DLQI and PASI scores benefit most from biologics18
	Skindex‐29, a QoL scoring system, does not correlate with improvements in PASI19
	DLQI is an independent predictor of work productivity20
Patient/physician goals	Achieving PASI‐75 leads to improvement of the HRQoL index (lack of direct correlation of PASI with DLQI)21, 22
	The Patient Benefit Index can be used as goal attainment scaling tool23
Questionnaires	When addressing the patient, the physician should use simple language and improve the patient′s psychological skills24
	It is important to communicate to the patient:24
	(i) That the physician understands the disease
	(ii) That there is hope of cure
	(iii) The perception of control
Patient‐reported outcomes	A clear definition of patient‐reported outcomes is needed
	Biologics also have a benefit on non‐PASI outcomes3
Satisfaction	Patients with high disease severity need a patient‐centred approach, as they are often dissatisfied with therapy25
	A study of 1293 patients revealed that topical therapy was significantly associated with least satisfaction; highest satisfaction was seen with biologics5
	For satisfaction, patients rated treatment effectiveness as most important, followed by treatment safety and doctor/patient communication5
Patient benefit index	PBI is a suitable instrument for the assessment of the patient‐reported benefit8
	More tools for understanding parameters of patient benefit and satisfaction are needed26

DLQI, dermatology quality of life index; HRQoL, health‐related quality of life; PASI, psoriasis area severity index.